COCP icon

Cocrystal Pharma

1.85 USD
-0.01
0.54%
At close Feb 14, 4:00 PM EST
1 day
-0.54%
5 days
2.78%
1 month
-7.04%
3 months
-15.91%
6 months
8.82%
Year to date
-20.26%
1 year
16.35%
5 years
-70.91%
10 years
-96.75%
 

About: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Employees: 12

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

43% more funds holding

Funds holding: 14 [Q2] → 20 (+6) [Q3]

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.14% less ownership

Funds ownership: 7.22% [Q2] → 7.08% (-0.14%) [Q3]

26% less capital invested

Capital invested by funds: $1.71M [Q2] → $1.27M (-$444K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
278%
upside
Avg. target
$7
278%
upside
High target
$7
278%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
39% 1-year accuracy
131 / 332 met price target
278%upside
$7
Buy
Reiterated
22 Jan 2025

Financial journalist opinion

Negative
Benzinga
1 month ago
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Neutral
GlobeNewsWire
1 month ago
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, placebo-controlled Phase 2a study is evaluating the safety, tolerability, pharmacokinetics (PK), antiviral activity and clinical measurements of CC-42344 at a single site in the United Kingdom.
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Neutral
GlobeNewsWire
5 months ago
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .'s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
Neutral
Accesswire
6 months ago
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
Positive
Zacks Investment Research
8 months ago
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Cocrystal Pharma, Inc. (COCP) could be a good stock pick from a technical perspective. COCP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Neutral
GlobeNewsWire
9 months ago
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
BOTHELL, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Neutral
GlobeNewsWire
9 months ago
Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344. CC-42344 is a new class of antiviral treatment designed to effectively block an essential step in the viral replication and transcription of pandemic and seasonal influenza A, and was discovered using the Company's proprietary structure-based drug discovery platform technology.
Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Neutral
GlobeNewsWire
10 months ago
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
BOTHELL, Wash., March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Neutral
GlobeNewsWire
11 months ago
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A.
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Neutral
Accesswire
11 months ago
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses, according to the company's website (see here: https://www.cocrystalpharma.com/). Click the following link to watch the Video Interview: Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts You can follow Planet MicroCap on TWITTER, LINKEDIN, YOUTUBE Please review important disclosures on our website at: https://snn.network/terms-of-use About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses.
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
Charts implemented using Lightweight Charts™